PD-1 Immune Checkpoint Inhibitor Therapy Malignant Tumor Based on Monotherapy and Combined Treatment Research
| Autor: | Yu Zhang, Guang-Ze Mou, Tian-Zhu Li, Wan-Ting Xu, Tong Zhang, Hui Xue, Wen-Bo Zuo, Yan-Nan Li, Ying-Hua Luo, Cheng-Hao Jin |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: | |
| Zdroj: | Technology in Cancer Research & Treatment, Vol 20 (2021) |
| Druh dokumentu: | article |
| ISSN: | 1533-0338 15330338 |
| DOI: | 10.1177/15330338211004942 |
| Popis: | Recently, immunotherapy has become the fourth pillar of cancer treatment in addition to surgery therapy, chemotherapy, and radiation therapy. The inhibitors of programed cell death protein 1 (PD-1) and its ligand PD-L1 are the new stars in immunotherapy, as they can overcome tumor immunosuppression. However, the efficacy of PD-1 inhibitors still needs to be further developed for clinical treatment. Therefore, research into treatment with anti-PD-1 drugs has emerged as a new development field. This review provides novel insights into the role and mechanism of PD-1 combination anti-tumor therapy, thereby promoting its clinical application in anti-tumor immunotherapy. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|